Pharmacokinetics of long-term sufentanil infusion for sedation in ICU patients.

Objective: To determine the pharmacokinetics of long-term infusion of sufentanil in ICU patients.

Design And Setting: Open-label study in a surgical intensive care unit.

Patients: Ten consecutive patients without renal or hepatic failure requiring mechanical ventilation for at least 6 days.

Pilot study on the effect of tourniquet use on sufentanil pharmacokinetics.

Study Objective: To test our hypothesis that sequestration of sufentanil can occur during surgery when a pneumatic tourniquet is used.

Design: Prospective, randomized study.

Setting: Operating room and recovery room of a university hospital.

Performance of target-controlled sufentanil infusion in obese patients.

Background: Because obesity might affect pharmacokinetic parameters, the authors evaluated the accuracy of target-controlled sufentanil infusion in morbidly obese patients using a pharmacokinetic model usually applied to a normal-weight population.

Methods: Target-controlled propofol and sufentanil coinfusions were administered to 11 morbidly obese patients (body mass index: 45.0 +/- 6.

Pharmacokinetics of itraconazole oral solution in neutropenic children during long-term prophylaxis.

We investigated the pharmacokinetics and safety of an oral solution of itraconazole in two groups of neutropenic children stratified by age. Effective concentrations of itraconazole in plasma were reached quickly and maintained throughout treatment. The results indicate a trend toward higher concentrations of itraconazole in plasma in older children.

Pharmacokinetics of sabeluzole and dextromethorphan oxidation capacity in patients with severe hepatic dysfunction and healthy volunteers.

Aims: The primary objective of this study was to determine how the pharmacokinetics of sabeluzole, an investigational drug with specific effects on memory and learning abilities, are affected by chronic liver disease. Since sabeluzole is metabolised by CYP2D6, a secondary objective was to study the correlation between CYP2D6 activity (as assessed by the dextromethorphan dextrorphan metabolic ratio) and hepatic dysfunction.

Methods: The single-dose pharmacokinetics of sabeluzole (10 mg) was compared in 10 healthy Caucasian subjects and 10 patients with severe hepatic dysfunction.